International Stem Cell (ISCO)
OTHER OTC:ISCO
Want to see ISCO full AI Analyst Report?
ISCO Stock Chart & Stats
$0.12
$0.02(17.61%)
At close: 4:00 PM EST
$0.12
$0.02(17.61%)
Day’s Range― - ―
52-Week Range$0.11 - $0.27
Previous CloseN/A
Volume134.00
Average Volume (3M)2.04K
Market Cap
$1.48M
Enterprise Value$3.95M
Total Cash (Recent Filing)$933.00K
Total Debt (Recent Filing)$3.52M
Price to Earnings (P/E)―
Beta0.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding8,004,389
10 Day Avg. Volume3,590
30 Day Avg. Volume2,041
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.28
Price to Sales (P/S)0.12
P/FCF Ratio-32.02
Enterprise Value/Market Cap2.67
Enterprise Value/Revenue0.43
Enterprise Value/Gross Profit0.75
Enterprise Value/Ebitda-89.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin SustainabilityConsistently high gross margins indicate the company’s products/services have durable unit economics. That margin buffer supports gross profitability even with volatile revenue, giving management room to invest in R&D or sales while pursuing a path to operating leverage if top-line stabilizes.
Diversified Revenue ModelMultiple revenue channels (product sales, licensing/milestones, and grants) reduce reliance on a single cash source. Licensing/collaboration income can provide non-dilutive milestone payments, while product sales offer recurring cash — structurally lowering single-point failure risk.
Prior Positive Operating Cash FlowHistory of positive operating cash flow shows the business can generate cash under improved conditions. This demonstrates operational leverage potential: with stabilized revenue or cost discipline, ISCO has a demonstrated pathway to rebuild free cash flow and fund near-term development.
Bears Say
Weak Balance SheetRepeated periods of negative equity and materially fluctuating debt create financial fragility. That weak capitalization reduces flexibility to fund R&D or scale, raises refinancing and covenant risk, and can deter large partners or investors for longer-term projects.
Deteriorating Cash GenerationOperating cash flow declined from positive to near-zero and free cash flow turned negative recently. Persistent weak cash conversion limits the firm’s ability to self-fund operations and R&D, increasing probability of dilution or external financing over the medium term.
Stagnant To Declining RevenueA flat multi-year top line followed by a recent revenue decline undermines scale benefits and prolongs the time to profitability. Without consistent revenue growth, the company faces harder trade-offs between investing for growth and restoring margins, pressuring long-term competitiveness.
International Stem Cell News
ISCO FAQ
What was International Stem Cell’s price range in the past 12 months?
International Stem Cell lowest stock price was $0.11 and its highest was $0.27 in the past 12 months.
What is International Stem Cell’s market cap?
International Stem Cell’s market cap is $1.48M.
When is International Stem Cell’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were International Stem Cell’s earnings last quarter?
Currently, no data Available
Is International Stem Cell overvalued?
According to Wall Street analysts International Stem Cell’s price is currently Overvalued.
Does International Stem Cell pay dividends?
International Stem Cell does not currently pay dividends.
What is International Stem Cell’s EPS estimate?
International Stem Cell’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does International Stem Cell have?
International Stem Cell has 8,004,389 shares outstanding.
What happened to International Stem Cell’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of International Stem Cell?
Currently, no hedge funds are holding shares in ISCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
International Stem Cell
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also develops, manufactures, and commercializes anti-aging skincare products and an extensive range of human cell culture products. Its diverse portfolio of human cell culture products serves as vital research tools across numerous scientific disciplines. This includes specialized cells and reagents designed for studying: Dermatology: Skin diseases, toxicology, and wound healing. Cardiovascular & Oncology: Heart and blood vessel conditions, and various cancers. Respiratory: Bronchial and tracheal conditions, toxicity, cystic fibrosis, asthma, and pathogenesis. Reproductive & Urological: Prostate, renal, bladder, corneal, and female reproductive system diseases, as well as general cellular physiology. Musculoskeletal & Metabolic: Skeletal muscle biology, diabetes, insulin pathways, muscle repair, and myotube development. The company also provides adult stem cells for regenerative medicine research and a full complement of reagents and supplements essential for cell growth, staining, and cryopreservation. Distribution of ISCO's skincare range occurs via its website and specialized professional channels, while its human cell culture products reach customers through a dedicated sales force, original equipment manufacturer (OEM) partners, and authorized brand distributors. Established in 2001, International Stem Cell Corporation maintains its headquarters in San Diego, California.
Technical Analysis
Ownership Overview
0.46%
Insiders
<0.01% Other Institutional Investors
99.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---